Anand Prasad, MD
Interventional Cardiology · San Antonio, TXNPI 1255538682
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $186,791 of the $306,004 with a category attached, or 61.0%. 36 manufacturers reported payments, led by Shockwave Medical, Inc at 30.2% of the total. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 483 payments — averaging $633.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$92K
- AstraZeneca$42K
- GE HealthCare$35K
- Bard Peripheral Vascular, Inc.$35K
- Osprey Medical Inc$32K
- Chiesi USA, Inc.$17K
- plus $52K from 30 others
Across 6 payments — averaging $3948.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Recor Medical Inc$19K
- Sanofi US Services Inc.$3K
- Acist Medical Systems, Inc.$2K
What the payments were for
- Consulting fees$82,47327%
- Speaking & faculty fees$186,79161%
- Travel & lodging$19,6376%
- Food & beverage$16,9036%
- Education$1170%
- Gifts$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 50 | $92,470 |
| AstraZeneca | 48 | $42,410 |
| GE HealthCare | 23 | $35,236 |
| Bard Peripheral Vascular, Inc. | 25 | $34,670 |
| Osprey Medical Inc | 37 | $32,412 |
| Chiesi USA, Inc. | 24 | $16,891 |
| Bayer | 10 | $13,857 |
| Abiomed | 40 | $12,094 |
| Medtronic(2 entities) | 35 | $7,529 |
| Sanofi-aventis U.S. LLC | 4 | $5,339 |
| Novartis | 8 | $3,439 |
| Premier Healthcare Solutions, Inc. | 2 | $2,200 |
| Biotronik Inc. | 43 | $1,426 |
| Amgen | 7 | $1,424 |
| Abbott | 50 | $1,122 |
| Teleflex LLC | 8 | $686 |
| Johnson & Johnson(2 entities) | 25 | $612 |
| Edwards Lifesciences | 3 | $315 |
| Penumbra, Inc. | 4 | $277 |
| Cardiva Medical, Inc. | 3 | $242 |
| Janssen Scientific Affairs, LLC | 3 | $229 |
| Angiodynamics, Inc. | 6 | $142 |
| Philips North America LLC | 3 | $138 |
| Boston Scientific | 2 | $130 |
| Heartflow, Inc. | 1 | $128 |
| Inari Medical, Inc. | 2 | $120 |
| Acist Medical Systems, Inc. | 3 | $111 |
| Actelion Pharmaceuticals US, Inc. | 5 | $110 |
| Calliditas Therapeutics US Inc. | 1 | $104 |
| Imperative Care, Inc | 1 | $32 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Kerecis Limited | 2 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| Avinger Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$87,240
- FARXIGA$41,304
- DyeVert$32,173
- KENGREAL$15,196
- Kerendia$13,533
- Impella$10,972
- Abre$5,793
- VISIPAQUE$5,716
- DISEASE STATE$5,322
- Vascular Lithotripsy$4,625
- LEQVIO$3,375
- CLEVIPREX$1,321
- VENOVO$970
- RotarexS 6 F x 135 cm$820
- HawkOne$611
- Orsiro Mission$387
- TurboHawk$293
- GUIDELINER$262
- Repatha$250
- Resolute$246
How this compares
$306,004 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 51 | $53,422 |
| FarxigaDapagliflozin Propanediol | 33 | $52,826 |
| EliquisApixaban | 39 | $39,773 |
| BrilintaTicagrelor | 47 | $29,133 |
| JardianceEmpagliflozin | 22 | $22,608 |
| Repatha SureclickEvolocumab | 36 | $22,376 |
| EntrestoSacubitril/Valsartan | 11 | $16,116 |
| VascepaIcosapent Ethyl | 13 | $10,068 |
| Ranolazine ErRanolazine | 34 | $4,543 |
| Icosapent Ethyl | 11 | $2,823 |
| Atorvastatin Calcium | 132 | $1,642 |
| Ezetimibe | 92 | $1,585 |
| Prasugrel Hcl | 31 | $1,271 |
| Amlodipine Besylate | 156 | $993 |
| Carvedilol | 100 | $862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $42,410 | $81,95980 claims |
| Johnson & JohnsonXarelto | $612 | $53,42251 claims |
| NovartisEntresto | $3,439 | $16,11611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in San Antonio
- Robert ChiltonSan Antonio$1.3M
- Nandish ThukralSan Antonio$259K
- Marvin EngSan Antonio$148K
- Chad ChristophersonSan Antonio$126K
- Vikas BhallaSan Antonio$123K
- Shah-Hinan AhmedSan Antonio$113K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.